U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.Bi
Molecular Weight 398.0801
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BISMUTH CITRATE

SMILES

[Bi+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=ANERHPOLUMFRDC-UHFFFAOYSA-K
InChI=1S/C6H8O7.Bi/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3

HIDE SMILES / InChI

Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Bi
Molecular Weight 208.9804
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/bibrocathol.html | https://clinicaltrials.gov/ct2/show/NCT01357538 | https://www.drugs.com/international/noviform.html | https://www.ncbi.nlm.nih.gov/pubmed/17003947

Bibrocathol (trade names Noviform and Posiformin) is a well-established topical antiseptic for the treatment of acute eyelid diseases like blepharitis. Eye ointments containing 2 or 5 % bibrocathol and the excipients liquid paraffin, white soft paraffin, and lanolin have been marketed since 1967 for the treatment of eye irritation, chronic blepharitis, and uninfected corneal injuries. Reports of clinical experience with bibrocathol for inflammation of the edge of the palpebra exist since the beginning of the 20th century. Until recently, no controlled, randomized clinical studies according to the guidelines for Good Clinical Practice for Trials on Medical Products for Human Use (GCP) as defined by the International Conference on Harmonisation (ICH) have been performed with bibrocathol 2 % ointment, as these were not required for marketing authorization in the 1960s. A first double-blind, prospective, controlled, GCP-compliant clinical study was recently performed to assess the efficacy of bibrocathol 5 % (Noviform®) in acute blepharitis. It demonstrated superior efficacy of bibrocathol 5 % ointment as compared to an ointment vehicle (placebo) after 2 weeks of treatment as assessed by a combined measure of slit-lamp examination results and patients’ subjective complaints.

Originator

Sources: Medizinische Klinik (Muenchen, Germany) (1913), 8, 992.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Noviform

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Successful treatment of blepharitis with bibrocathol (Posiformin® 2 %).
2012 Dec
Patents

Sample Use Guides

A strip of 5 mm eye ointment applied 3 times per day to the eye lid
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:53:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:53:47 GMT 2023
Record UNII
N04867Y76N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BISMUTH CITRATE
INCI   MART.   USP   USP-RS   WHO-DD  
INCI  
Official Name English
TEGOKAT 752
Common Name English
BISMUTH CITRATE [INCI]
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, BISMUTH(3+) SALT (1:1)
Common Name English
BISMUTH CITRATE [MART.]
Common Name English
BISMUTH CITRATE [USP MONOGRAPH]
Common Name English
Bismuth citrate [WHO-DD]
Common Name English
BISMUTH CITRATE [USP-RS]
Common Name English
Classification Tree Code System Code
DSLD 3466 (Number of products:4)
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
NCI_THESAURUS C266
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
Code System Code Type Description
CAS
813-93-4
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
FDA UNII
N04867Y76N
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
ECHA (EC/EINECS)
212-390-1
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
NCI_THESAURUS
C78025
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
EVMPD
SUB32895
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
PUBCHEM
13135
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID6074330
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
MESH
C002791
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
SMS_ID
100000126277
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
RS_ITEM_NUM
1075531
Created by admin on Fri Dec 15 15:53:48 GMT 2023 , Edited by admin on Fri Dec 15 15:53:48 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY